Literature DB >> 11064608

Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans.

H Gottrup1, F W Bach, L Arendt-Nielsen, T S Jensen.   

Abstract

We examined the effect of the subcutaneous infiltration of ketamine, lidocaine and saline before injury on capsaicin-induced pain and hyperalgesia. Twelve healthy volunteers participated in two separate, randomized, double-blind, placebo-controlled crossover experiments. In experiment 1, 100 micrograms capsaicin was injected intradermally in one volar forearm 10 min after the skin had been pretreated with lidocaine 20.0 mg in 2.0 ml or 0.9% saline 2.0 ml at the capsaicin injection site. In experiment 2, a similar capsaicin test was given 10 min after the skin had been pretreated with ketamine 5 mg in 2.0 ml or 0.9% saline 2.0 ml. To control for possible systemic effects, the capsaicin injection site was pretreated by injection of saline into the skin and the contralateral arm was treated with active drug, and vice versa. Outcome measures were spontaneous pain, pain evoked by punctate and brush stimuli, and areas of brush-evoked and punctate-evoked hyperalgesia. Lidocaine reduced all measures compared with placebo (P < 0.001), whereas ketamine failed to change any measures. Pain scores and areas of hyperalgesia were not affected when the contralateral site was infiltrated with ketamine or lidocaine. Lidocaine produced no side-effects, whereas ketamine produced paraesthesia, dizziness and sleepiness in six out of 24 (25%) cases. Blocking peripheral sodium channels with locally administered lidocaine reduces spontaneous pain and capsaicin-induced hyperalgesia but local block with the NMDA-type glutamate receptor antagonist ketamine has no effect on capsaicin-induced pain and hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064608     DOI: 10.1093/bja/85.4.520

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.

Authors:  Béatrice Astruc; Antoine Tarral; Philippe Dostert; Fabrizia Mariotti; Laura Fabbri; Bruno P Imbimbo
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 2.  A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.

Authors:  Guido van Amerongen; Matthijs W de Boer; Geert Jan Groeneveld; Justin L Hay
Journal:  Br J Clin Pharmacol       Date:  2016-07-08       Impact factor: 4.335

3.  Area 3a neuron response to skin nociceptor afferent drive.

Authors:  Barry L Whitsel; Oleg V Favorov; Yongbiao Li; Miguel Quibrera; Mark Tommerdahl
Journal:  Cereb Cortex       Date:  2008-06-04       Impact factor: 5.357

4.  Glutamate and capsaicin-induced pain, hyperalgesia and modulatory interactions in human tendon tissue.

Authors:  William Gibson; Lars Arendt-Nielsen; Barry J Sessle; Thomas Graven-Nielsen
Journal:  Exp Brain Res       Date:  2009-01-13       Impact factor: 1.972

Review 5.  Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.